|
|
|
|
- PPB: She's not a director. The previous speakers have spoken. I have the written speach from the director. National drug regulatory authority. We're involved in RCT were we try to get the input of the scientists. One of our mandates is to have products with quality, efficacious and safe. When it is needed, it has to be available. When a product is licensed by the PPB. Ghana people, we privileged to have you. We're in touch with the Ghana FDA, we have counterparts. We can consult with them. For a long time alb and mlb. The need for repeated dosing. The one health guideline development group recomended further research in alternative antihelminthic medication or combination to avoid resistance development. The prooposed fdc of alb/ivm represents a promising advancement for those ailed by this disease. the ppb is commited to: 1: ensure that all mediciens approved meet the highest standards of safety, efficacy and quality. we'll evaluate the fdc to ensure that it meets those standards. 2) We appreciate your RCT your expertise we pledge to mantain transparency in this process keeping all stakeholders engaged. postmarket surveillance to ensure ongoing safety and efficacy. I reiterate the board commitment to improve public health through the approval and disemination of safe and effective medicines. we can improve the lifes of millions in kenya and globally. we're particularly optimistic about this initiative.
|
FMS
7 months ago